NEXGEL (NASDAQ:NXGL) reported second-quarter 2026 revenue of $3.69 million and a net loss of $2.87 million as the healthcare products company worked through a slower-than-expected integration and commercial rollout of its newly formed BioNX Surgical division.
The Q2 results highlight a transition period following NEXGEL’s April transaction with Celularity, with supply constraints contributing to a roughly $795,000 BioNX Surgical backlog while the company prepares new hospital, regenerative eye health and aesthetics initiatives for the second half of 2026.
Key Investor Takeaways
- NEXGEL (NASDAQ:NXGL) generated Q2 revenue of $3.69 million while recording a $2.87 million net loss.
- The loss included $756,554 of BioNX intangible asset amortisation, $273,710 of one-time transaction expenses and $144,495 related to the SilverSeal Amazon inventory recall.
- BioNX Surgical currently has an approximately $795,000 backlog as supply chain constraints continue to affect product availability.
- The BioNX integration and surgical-channel revenue ramp have progressed more slowly than management originally anticipated.
- Investors have several near-term milestones to monitor, including SilverSeal’s hospital rollout, manufacturing technology transfer and a planned investor update around September 15.
Why NXGL Stock Is in Focus
The quarter reflects the initial financial and operational impact of NEXGEL’s transaction with Celularity, which closed in mid-April. Since then, the company has been integrating employees, sales representatives and customer relationships while aligning operations and marketing around BioNX Surgical.
Management acknowledged that expansion into the surgical channel has taken longer than expected, with manufacturing constraints adding another obstacle to the commercial ramp.
Sequence Life Science deployed tissue processing specialists to Celularity’s New Jersey facility on August 4 as part of plans to transfer manufacturing technology and future production capabilities to Sequence’s San Antonio, Texas facility.
The initiative is intended to address longer-term supply constraints and improve manufacturing scalability. In the meantime, limited product availability has contributed to the approximately $795,000 BioNX Surgical backlog.
NEXGEL’s $2.87 million quarterly net loss also included several items management identified as non-recurring or non-cash. These comprised $756,554 of intangible asset amortisation, $273,710 in transaction-related costs and $144,495 associated with recalling SilverSeal inventory from Amazon.
Why This Matters for Investors
The central issue heading into the second half is whether NEXGEL can convert its BioNX backlog and expanded commercial infrastructure into revenue as product availability improves.
The manufacturing transfer could help address the supply constraints that have limited the initial rollout, but management’s acknowledgement of slower integration and revenue progression introduces execution uncertainty around the timing of that opportunity.
SilverSeal represents another change in commercial strategy. NEXGEL recalled its Amazon inventory ahead of an August launch into the hospital market. The product already has reimbursement A-codes that provide coverage opportunities across physician offices, ambulatory surgery centres and hospitals for surgical and wound-care applications.
Management believes hospital sales could generate greater volumes and higher gross margins than existing distribution channels. Execution of that transition may therefore influence both revenue growth and the company’s margin profile.
NEXGEL is also broadening BioNX through the launch of BioNX Regenerative Eye Health & Aesthetics. The initiative uses exclusively licensed Sequence products and targets ocular and aesthetic applications, adding another potential commercial channel while the core surgical business continues its integration.
Capital-markets flexibility is also in focus. Shareholders did not provide sufficient support for proposals covering an increase in authorised shares and reverse stock split authority during the company’s recent proxy solicitation.
NEXGEL plans to seek approval again with the measures presented independently of the previously linked redomicile proposal. Management expects the process to conclude in late September.
What to Watch Next
Product availability and the conversion of the approximately $795,000 BioNX Surgical backlog will provide an indication of whether manufacturing constraints are beginning to ease.
Investors can also monitor the transfer of production capabilities to Sequence’s San Antonio facility, the hospital rollout of SilverSeal and early progress from BioNX Regenerative Eye Health & Aesthetics.
The company has also regained access to approximately $710,000 of restricted cash since quarter-end following the conclusion of its relationship with ATW Partners.
NEXGEL expects to hold an investor update call on or around September 15, 2026, covering operational progress, commercialisation initiatives and expectations for the remainder of the year.